![]() ![]() IRC# 07102-01.Īn open label extension study for subjects previously treated in either pilot I or pilot II studies of the application of magnetic fields using the Resonator™ for the treatment of Parkinson's Disease: Extension pilot study protocol, Version 4.0, March 14, 2008. IRC # 07021-02.Ī double-blind, sham-stimulation controlled study of the application of magnetic fields using the Jacobson Resonator™ for the treatment of Parkinson's Disease: phase two pilot study protocol. These protocols involved Parkinson Disease, Alzheimer Disease, Fibromyalgia, and Type 2 Diabetes patients for eight independent studies, as described below:Įfficacy of the application of magnetic fields to the treatment of Parkinson's Disease pilot study protocol, APPLIED MAGNETICS, LLC. IRB, Western Investigational Review Board (WIRB), University of Colorado's IRB (COMIRB), Ethical & Independent Review Services, and University of South Florida's IRB determined the Magnesphere's™ predecessor device, the Resonator™, to be a non-significant risk (NSR) device when applied to the particular studies and protocols identified below. To date, five Institutional Review Boards (IRBs), including Independent Review Consulting, Inc. There are no other hazards that the Company has identified with this device. Since the magnetic therapy that is produced by this device is in the Pico-Tesla range, the magnetic energy that is delivered to the body is a fraction of the magnetic energy produced by the earth on a constant basis. It is possible that you may suffer discomfort or pain, but it is not likely. The FDA has not decided that the Magnesphere™ device or exposure to it is safe. It is possible that there are other medical risks from exposure to the Magnesphere™ as we do not know all of the consequences from its use. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |